VIVORYON THERAPEUTICS NV (VVY.AS) Stock Price, Quote, News and Overview
AMS:VVY - Euronext Amsterdam - NL00150002Q7 - Common Stock - Currency: EUR
VVY.AS Quote, Performance and Key Statistics
AMS:VVY (3/7/2025, 7:00:00 PM)
1.93
+0.03 (+1.58%)
The current stock price of VVY.AS is 1.93 EUR. In the past month the price decreased by -0.31%. In the past year, price increased by 277.69%.
VVY.AS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
| 1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
| AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
| 1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
| GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
| ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
| IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
| 1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
| 0QF.DE | MODERNA INC | N/A | 13.19B |
Related stock screener links
About VVY.AS
Company Profile
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. The company is headquartered in Halle, Sachsen-Anhalt and currently employs 15 full-time employees. The company went IPO on 2014-10-27. The firm is developing a directed pipeline of product candidates with the project being a therapeutic approach for the treatment of AD. Its operations focus on the discovery and development of therapeutic programs, whereas operational research and development work is mainly outsourced to respective professional contract research organizations (CROs) or academic collaboration partners. Vivoryon strives to generate future revenues from licensing its product candidates to biopharmaceutical companies after development steps have been achieved or by commercializing products.
Company Info
VIVORYON THERAPEUTICS NV
Weinbergweg 22
HALLE SACHSEN-ANHALT DE
Employees: 15
Company Website: https://www.vivoryon.com/
Investor Relations: http://www.vivoryon.com/investors-news/
Phone: 493455559900
VIVORYON THERAPEUTICS NV / VVY.AS FAQ
What is the stock price of VIVORYON THERAPEUTICS NV today?
The current stock price of VVY.AS is 1.93 EUR. The price increased by 1.58% in the last trading session.
What is the ticker symbol for VIVORYON THERAPEUTICS NV stock?
The exchange symbol of VIVORYON THERAPEUTICS NV is VVY and it is listed on the Euronext Amsterdam exchange.
On which exchange is VVY.AS stock listed?
VVY.AS stock is listed on the Euronext Amsterdam exchange.
What is the price forecast or stock price prediction for VIVORYON THERAPEUTICS NV stock?
8 analysts have analysed VVY.AS and the average price target is 5.36 EUR. This implies a price increase of 177.46% is expected in the next year compared to the current price of 1.93. Check the VIVORYON THERAPEUTICS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VIVORYON THERAPEUTICS NV worth?
VIVORYON THERAPEUTICS NV (VVY.AS) has a market capitalization of 50.32M EUR. This makes VVY.AS a Micro Cap stock.
How many employees does VIVORYON THERAPEUTICS NV have?
VIVORYON THERAPEUTICS NV (VVY.AS) currently has 15 employees.
What are the support and resistance levels for VIVORYON THERAPEUTICS NV (VVY.AS) stock?
VIVORYON THERAPEUTICS NV (VVY.AS) has a support level at 1.79 and a resistance level at 1.93. Check the full technical report for a detailed analysis of VVY.AS support and resistance levels.
Should I buy VIVORYON THERAPEUTICS NV (VVY.AS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VVY.AS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VVY.AS, evaluating the profitability, health, valuation and growth aspects
- VIVORYON THERAPEUTICS NV (VVY.AS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VIVORYON THERAPEUTICS NV (VVY.AS) Sales and EPS estimates to see what analysts future expectations are.
- VIVORYON THERAPEUTICS NV (VVY.AS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VIVORYON THERAPEUTICS NV (VVY.AS) Insider and Institutional Ownership to learn about the owners and their transactions.
- VIVORYON THERAPEUTICS NV (VVY.AS) Stock Chart to make your own analysis
- VIVORYON THERAPEUTICS NV (VVY.AS) Latest news and press-releases to stay up to date.
Does VIVORYON THERAPEUTICS NV (VVY.AS) stock pay dividends?
VVY.AS does not pay a dividend.
When does VIVORYON THERAPEUTICS NV (VVY.AS) report earnings?
VIVORYON THERAPEUTICS NV (VVY.AS) will report earnings on 2025-04-22, after the market close.
What is the Price/Earnings (PE) ratio of VIVORYON THERAPEUTICS NV (VVY.AS)?
VIVORYON THERAPEUTICS NV (VVY.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.2).
VVY.AS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to VVY.AS. When comparing the yearly performance of all stocks, VVY.AS is one of the better performing stocks in the market, outperforming 99.77% of all stocks.
VVY.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VVY.AS. While VVY.AS has a great health rating, there are worries on its profitability.
VVY.AS Financial Highlights
Over the last trailing twelve months VVY.AS reported a non-GAAP Earnings per Share(EPS) of -1.2. The EPS decreased by -7.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -166.81% | ||
| ROE | -202.73% | ||
| Debt/Equity | 0 |
VVY.AS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to VVY.AS. The Buy consensus is the average rating of analysts ratings from 8 analysts.